Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.2380
+0.0016 (0.69%)
Jul 30, 2025, 3:59 PM EDT
Northwest Biotherapeutics Employees
Northwest Biotherapeutics had 25 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
25
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$58,920
Profits / Employee
-$3,436,800
Market Cap
351.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | 0 | - |
| Dec 31, 2023 | 25 | 3 | 13.64% |
| Dec 31, 2022 | 22 | 3 | 15.79% |
| Dec 31, 2021 | 19 | 0 | - |
| Dec 31, 2020 | 19 | 2 | 11.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Northwest Biotherapeutics News
- 7 weeks ago - Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments - PRNewsWire
- 3 months ago - Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval - Seeking Alpha
- 7 months ago - Northwest Biotherapeutics announces $5M convertible note financing and standby facility for up to $50M additional financing - Seeking Alpha
- 7 months ago - Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing - PRNewsWire
- 8 months ago - Northwest Biotherapeutics: All Is Not Well With This One - Seeking Alpha
- 1 year ago - Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors - PRNewsWire